bit.bio
Cambridge · Financial Services, Information Technology, Payments · 162 employees
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at a
Funding history
- Funding Round · $50.0M · Jan 2026
- Series B · Undisclosed · Nov 2021
Recent signals
- Aug 13, 2026: bit.bio Appoints Sejla Salic-Hainzl as Chief Technology Officer
- Jan 09, 2026: Raised $50.0M in Funding Round
- Mar 19, 2025: UK cell therapy biotech bit.bio pivots to tool development, forms partnership with BlueRock Therapeutics
- Jan 27, 2025: Launched bit.bio Introduces ioTracker Cells Range to Enhance Neurodegenerative Disease Research at SLAS 2025.
- Oct 16, 2024: Launched bit.bio Successfully Defends Patent for opti-ox™ Cell Programming Technology to Enhance Pluripotent Stem Cell Applications
- Jul 31, 2024: bit.bio Appoints Przemek Obloj as Chief Financial Officer
- Nov 05, 2021: Raised funding in Series B
See plans & pricing → Track bit.bio’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches bit.bio across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.